摘要
目的:临床观察和评估新一代氟喹诺酮类药物莫西沙星联合治疗耐多药肺结核病(MDR-TB)的疗效及其安全性。方法:将38例耐多药肺结核(MDR-TB)患者随机分为治疗组20例和对照组18例;治疗组化疗方案为:6RftPaAmMxZ/12RftPaMxZ。对照组化疗方案为:6RftPaAmLfxZ/12RftPaLfxZ。所有病例疗程均为18个月。结果:治疗组疗程结束时痰菌阴转阴转率为90%。对照组疗程结束痰菌阴转阴转率为61.1%,两组阴转率比较差异有统计学意义(P<0.05)。疗程结束后治疗组总有效率为85%。对照组总有效率为61.1%,两组之间具有显著性统计学差异(P<0.05)。两组不良反应无统计学意义(P>0.05)。结论:以莫西沙星组成方案对MDR-TB疗效较好,不良反应低。
Objective： To observe and evaluate the efficacy and safety of the combination treatment of mecifloxacin, the new generation fluoroquinolones （FQNLs）, in multi-drug resistant tuberculosis （MDR-TB）. Methods： 38 MDR-TB patients were randomly divided into the treatment group （20 cases） and the control group （18 cases）. The treatment plans for the patients in the treatment group and the control group were 6 RftPaAmMxZ/12 RftPaMxZ and 6 RftPaAmLfxZ/12 Rft- PaLfxZ respectively, and the course of treatment for patients in both group was 18 months. Re- sults： At the end of the treatment, the negative conversion rate of sputum was 90% in the treat- ment group, while 61.1% in the control group, which was of statistical difference （P〈0.05）. The total effective rate was 85% in the treatment group and 61.1% in the control group, which was sig- nificantly different （P〈0.05）. However, there was no obvious difference of the adverse reaction in both group （P〈0.05）. Conclusion： The treatment plan containing moxifloxaxin is very effective in treating MDR-TB and with lower adverse reaction.
出处
《华夏医学》
CAS
2013年第1期76-79,共4页
Acta Medicinae Sinica
关键词
莫西沙星
肺结核
耐多药性
moxifloxaein
tuberculosis （TB）
multi-drug resistant
